TheraRadar
Clinical-Stage Companies / Xiamen Amoytop Biotech

Xiamen Amoytop Biotech

Pre-Approval PRO BETA
25
Total Trials
7
Phase 3
9
Phase 2
3
Recruiting
224
Score

Pipeline by Phase

Phase 3
7
Phase 2
9
Phase 1
9

Therapeutic Focus

Chronic Hepatitis B Preeclampsia Idiopathic Short Stature Small for Gestational Age Healthy

Clinical Trials (25)

NCT06927310 Phase 3 RECRUITING

The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature

Started: 4/28/2025

NCT07309562 Phase 3 RECRUITING

The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age

Started: 1/20/2026

NCT04846491 Phase 3 COMPLETED

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

Started: 12/4/2019

NCT04466137 Phase 3 COMPLETED

Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy

Started: 10/16/2020

NCT01760122 Phase 3 COMPLETED

Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Started: 3/1/2013

NCT01581398 Phase 3 COMPLETED

Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients

Started: 4/1/2012

NCT06552429 Phase 2 RECRUITING

Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET

Started: 8/29/2024

NCT05838885 Phase 2 COMPLETED

A Trial of YPEG-rhGH in Children With Short Stature

Started: 2/15/2022

NCT04513171 Phase 2 COMPLETED

Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children

Started: 12/26/2018

NCT04885647 Phase 2 COMPLETED

A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease

Started: 3/12/2021

NCT02005458 Phase 2 COMPLETED

Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

Started: 12/1/2013

NCT02332473 Phase 2 COMPLETED

A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B

Started: 6/1/2014

NCT01140997 Phase 2 COMPLETED

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C

Started: 7/1/2010

NCT01143662 Phase 2 COMPLETED

Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Started: 7/1/2010

NCT07551804 Phase 2 NOT YET RECRUITING

Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency

Started: 5/31/2026

NCT06924385 Phase 1 COMPLETED

Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing

Started: 4/6/2025

NCT07462455 Phase 1 NOT YET RECRUITING

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)

Started: 3/31/2026

NCT06716905 Phase 1 COMPLETED

Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants

Started: 3/6/2025

NCT07408908 Phase 1 NOT YET RECRUITING

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..

Started: 3/6/2026

NCT06893796 Phase 1 COMPLETED

Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females

Started: 3/26/2025

NCT01800305 Phase 1 COMPLETED

PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual

Started: 9/1/2012

NCT01238562 Phase 1 COMPLETED

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients

Started: 4/1/2010

NCT01339182 Phase 1 COMPLETED

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers

Started: 1/1/2011

NCT01343186 Phase 1 COMPLETED

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects

Started: 1/1/2011

NCT01232504 Phase 4 COMPLETED

Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT

Started: 9/1/2009

Drug Candidates

Telpegfilgrastim Injection ACT500 tablets Inpegsomatropin Injection Recombinant Human Growth Hormone Injection Placebo ACT100 Injection Placebo for ACT100 Peginterferon α-2b injection Peginterferon alfa-2b injection TDF
Activity Status: Active
Last Trial Started: 5/31/2026
Last Trial Ended: 1/20/2026
Trials (12 months): 4
Completed Trials: 19
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.